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Abstract 
Photodynamic therapy (PDT) is a developing cancer treatment involving the use of a photoactive 
drug molecule that is inactive in the dark and activated by low energy light. A new pathway that 
is being explored is the caging of cytotoxic molecules by protecting groups that are photolabile. 
Divalent ruthenium complexes exhibit photoinduced ligand exchange, making these complexes 
prime candidates for investigation as new PDT agents. The synthesis and characterization by 1H 
NMR of four ruthenium(II) complexes, [Ru(tpy)(NN)L](PF6)2 where NN = bpy (bpy = 2,2ʹ-
bipyridine) or dppn (dppn = benzo[i]-dipyrido[3,2-a:2ʹ,3ʹ-c]phenazine) and L = CH3CN or Cbz-
Leu-NHCH2CN, is reported. [Ru(tpy)(NN)Cbz-Leu-NHCH2CN](PF6)2 are proposed as potential 
PDT agents, as Cbz-Leu-NHCH2CN is a cathepsin K inhibitor capable of reducing or hindering 
tumor growth and metastasis. The photoinduced ligand exchange of all four complexes in water 
upon irradiation with visible light was monitored by electronic absorption spectroscopy. 
Complexes with a dppn ligand required longer irradiation times than complexes with a bpy 
ligand. The production of singlet oxygen in [Ru(tpy)(dppn)(CH3CN)]
2+  was tracked with 
emission spectroscopy and the use of an emissive singlet oxygen scavenger, DPBF = 1,3-
diphenylisobenzofuran, and the quantum yield is reported, ΦΔ = 0.62(6).  
 
Introduction 
The anticancer agent, cisplatin, cis-[Pt(NH3)Cl2], and its derivatives have proved effective 
treatments for a variety of cancers.[1-6] Cisplatin is activated upon entering the cell and 
exchanging the two chloride ligands for water molecules. In this form, cisplatin is able to bind to 
the bases of DNA, and inhibit cell proliferation and effect cell death. The process of ligand 
exchange between the chloride and water ligands is activated thermally, and thus makes the drug 
effective at targeting rapidly reproducing cells.[4-6] While this includes cancerous cells, cisplatin 
also targets healthy cells such as liver and hair cells, leading to a number of adverse effects.[5-6] 
Cisplatin is also selective to certain cancers but not others. Additionally, aggressive cancers, such 
as breast cancer, previously treated with a cisplatin-based treatment have also been shown to 
acquire a resistance to the drug. [1-6] 
 
New treatment modalities are being explored to avoid the adverse effects associated with 
cisplatin based treatments. A current FDA-approved treatment is photodynamic therapy (PDT). 
PDT relies on the activation of drug molecules that are otherwise nontoxic by excitation with 
low energy visible light.[7-9] Low energy visible light (ca. 600-900 nm) is able to penetrate up to 
2 cm of tissue, making it an ideal choice for activating drug molecules in membranes, cells, or in 
the vicinity of the tumor. This results in localized drug delivery centered on the cancerous 
region. 
 
Current FDA-approved PDT agents are highly conjugated aromatic molecules that when 
irradiated with low energy visible are capable of producing singlet oxygen. When these 
molecules are irradiated, they are excited to a high energy singlet excited state and then relax to a 
lower energy long-lived triplet excited state.[10] Energy transfer from the triplet state to molecular 
oxygen results in the formation of singlet oxygen, which has been shown to be cytotoxic.[7, 11, 12] 
However, many aggressive, solid tumors are hypoxic in nature, limiting this mode of action.[10] 
To further the applications of PDT, new agents should be toxic independent of oxygen 
concentration and capable of efficiently absorbing the low energy visible light necessary for 
activation. 
 Ru(II) polypyridyl complexes have been shown to exhibit photoinduced ligand exchange.[13-16] 
Upon irradiation, the complex is excited to a high energy 1MLCT (singlet metal-to-ligand charge 
transfer) state and rapidly undergoes intersystem conversion to the 3MLCT (triplet metal-to-
ligand charge transfer) state. From this state, the 3LF (triplet ligand field) state is accessible and 
ligand dissociation is possible.[17] This ability of Ru(II) complexes make them prime candidates 
for PDT as they are capable of localized light-activated drug delivery of a bound drug molecule. 
 
The drug molecule used is Cbz-Leu-NHCH2CN, a cathepsin K enzyme inhibitor.
[18] Cathepsin K 
has been shown to be overexpressed in bone marrow macrophages, osteoclasts, and breast cancer 
cells, and has been shown to promote tumor growth and metastasis. However, the enzyme is also 
important for function of healthy cells, such that inhibitors cannot be administered systemically 
to a patient. Therefore, the release of inhibitors in the vicinity of the tumor with light makes it a 
target for PDT.[18] Cbz-Leu-NHCH2CN is capable of binding to Ru(II) through the terminal 
nitrile (Figure 1), which prevents it from interacting with cathepsin K.[19] This makes Cbz-Leu-
NHCH2CN a prime candidate for use in a PDT agent as it is nontoxic in the dark when bound to 
Ru(II) and can be exchanged with a water molecule upon visible light irradiation in an aqueous 
environment, thus releasing the inhibitor for therapeutic action. 
 
Figure 1: Chemical structure of Cbz-Leu-NHCH2CN. 
 
Ru(II) complexes are capable of dual action cytotoxicity.[17] If a singlet oxygen-producing ligand 
is coordinated to the metal center, the complex is able to produce singlet oxygen upon irradiation 
as well as release a bound therapeutic molecule. The ligand used for singlet oxygen production in 
the present work is dppn (benzo[i]-dipyrido[3,2-a:2ʹ,3ʹ-c]phenazine). When dppn is bound to 
Ru(II), the complex has a low-lying, long-lived 3ππ* state capable of generating singlet oxygen 
with nearly 100% yield.[20] 
 
The complexes under investigation are [Ru(tpy)(bpy)(CH3CN)]
2+ (1; tpy = 2,2ʹ:6ʹ,2ʹʹ-terpyridine, 
bpy = 2,2ʹ-bipyridine,), [Ru(tpy)(dppn)(CH3CN)]2+ (2), [Ru(tpy)(bpy)(Cbz-Leu-NHCH2CN)]2+ 
(3) and [Ru(tpy)(dppn)(Cbz-Leu-NHCH2CN)]
2+ (4), and their molecular structures are shown in 
Figure 2. The acetonitrile complexes 1 and 2 were investigated as controls for the corresponding 
drug-containing complexes 3 and 4. 
 
Figure 2: The proposed complexes for study: (1) [Ru(tpy)(bpy)(CH3CN)]2+, (2) [Ru(tpy)(dppn)(CH3CN)]2+, (3) 
[Ru(tpy)(bpy)(Cbz-Leu-NHCH2CN)]2+, and (4) [Ru(tpy)(dppn)(Cbz-Leu-NHCH2CN)]2+ 
  
Experimental Section 
 
Materials 
Standard Schlenk-line techniques were used to maintain anaerobic conditions during the 
preparation of compounds when necessary. The solvents used were of reagent grade quality.  
Water (ChromAR, Mallinckrodt, or deionized to 18 MOhm), 200 proof ethanol (Decon 
Laboratories), diethyl ether (Fisher Scientific), acetone (Fisher Scientific), methanol (Fisher 
Scientific), dichloromethane (Macron), hexanes (Macron) were used as received. 
Dimethylformamide (Sigma-Aldrich) was distilled to dryness. The reagents RuCl3·3H2O 
(Pressure Chemicals), 2,2ʹ-bipyridine (Alfa Aesar), 2,2ʹ:6ʹ,2ʹʹ-terpyridine (Sigma-Aldrich), 
lithium chloride (Sigma-Aldrich), triethylamine (Fisher Scientific), ammonium hexafluorate 
(Sigma-Aldrich), acetonitrile (Fisher Scientific), silver triflate (Sigma-Aldrich), silver 
tetrafluoroborate (Sigma-Aldrich), sodium bicarbonate (Fisher Scientific), potassium chloride 
(Sigma-Aldrich), Z-L-Leu-OH-DCA (Chem Impex), aminoacetonitrile hydrochloride (Pfaltz-
Bauer), O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) 
(Indofine), potassium ferrioxalate (Strem Chemicals), and 1,3-diphenylisobenzofuran (DPBF, 
Sigma-Aldrich) were purchased and used without further purification. Celite (Jenneile) was used 
as received. Neutral alumina (Fisher Scientific) was deactivated with methanol. Deuterated 
acetone (Sigma-Aldrich), chloroform (Sigma-Aldrich), and acetonitrile (Sigma-Aldrich) were 
used as received. The dppn ligand was prepared according to literature procedures.[20]  
 
Synthesis of Ru(tpy)Cl3 
The synthesis of Ru(tpy)Cl3 was adapted from a reported procedure.
[21] A mixture of 
RuCl3·3H2O (560.5 mg, 2.14 mmol) and tpy (500.0 mg, 2.14 mmol) in 100 mL EtOH was heated 
at reflux for 4 hours. The reaction mixture was cooled to room temperature. The solid was 
collected by vacuum filtration and washed with EtOH (30 mL) and H2O (15 mL).  
 
Synthesis of [Ru(tpy)(bpy)Cl](PF6) 
Synthesis of [Ru(tpy)(bpy)Cl](PF6) was adapted from a reported procedure.
[22] Ru(tpy)Cl3 (100.5 
mg, 0.228 mmol) was dissolved in 3:1 EtOH:H2O (40 mL) with bpy (58 mg, 0.372 mmol), LiCl 
(90 mg, 2.12 mmol) and triethylamine (250 µL, 1.79 mmol) and heated at reflux for 4 hours. The 
reaction mixture was cooled to room temperature and stirred with excess NH4PF6. The solid was 
collected by vacuum filtration and washed with diethyl ether, and then dissolved in acetone and 
dried (yield = 41.4%).  
 
Synthesis of [Ru(tpy)(dppn)Cl](PF6)  
Ru(tpy)Cl3 (52.8 mg, 0.120 mmol), dppn (55.1 mg, 0.166 mmol), LiCl (45.0 mg, 1.06 mmol) and 
triethylamine (125 µL, 0.897 mmol) in 20 mL EtOH were heated at reflux for 4 hours. The 
reaction mixture was cooled to room temperature and stirred with NH4PF6. EtOH was removed 
with nitrogen, and the precipitate was collected by vacuum filtration and washed with H2O, 
acetone, and toluene. Purification was achieved by dissolving the resulting solid in CH2Cl2 and 
centrifuging to remove solid. The complex was eluted from an alumina column with CH2Cl2 
with 3% MeOH. A yellow band containing excess dppn eluted first, followed by a purple band 
containing the desired product. 
 
Synthesis of [Ru(tpy)(bpy)(CH3CN)](PF6)2 
Synthesis of [Ru(tpy)(bpy)(CH3CN)](PF6)2 was adapted from a reported procedure.
[23]  
[Ru(tpy)(bpy)Cl](PF6) (31.3 mg, 0.0466 mmol) was dissolved and heated at reflux in a 20 mL 
1:1 CH3CN:H2O mixture overnight. The reaction mixture was cooled to room temperature and 
stirred with NH4PF6. The solid was collected by vacuum filtration. 
1H NMR ((CD3)2CO) δ 2.07 
ppm (s, 3H), 7.04 (tq, 1H), 7.31 (m, 2H), 7.64 (dq, 2H), 7.77 (m, 1H), 7.94 (m, 3H), 8.29 (m, 
4H), 8.37 (dq, 2H), 8.51 (d, 2H), 8.58 (d, 1H), 9.56 (dq, 1H). 
 
Synthesis of [Ru(tpy)(dppn)(CH3CN)](PF6)2 
[Ru(tpy)(dppn)Cl](PF6) (33 mg, 0.0390 mmol) and AgSO3CF3 (9 mg, 0.0350 mmol) in 20 mL 
1:1 CH3CN:H2O were heated at reflux for 4 hours. The reaction was cooled to room temperature 
and stirred with NH4PF6. The solid was collected by vacuum filtration. 
1H NMR ((CD3)2CO) δ 
2.43 ppm (s, 3H), 7.45 (m, 2H), 7.76 (m, 1H), 7.80 (m, 2H), 8.09 (d, 2H), 8.16 (m, 3H), 8.44 (m, 
2H), 8.58 (t, 1H) 8.63 (q, 1H), 8.81 (dt, 2H) , 8.97 (dd, 2H), 9.15 (s, 1H), 9.25 (s, 1H). 9.52 (dd, 
1H), 10.03 (dd, 1H), 10.35 (dd, 1H). 
 
Synthesis of Cbz-Leu-NHCH2CN  
Cbz-Leu-NHCH2CN was synthesized according to a modified literature procedure.
[24] Z-L-Leu-
OH-DCA (1.8606 g, 446.6g/mol), aminoacetonitrile hydrochloride (0.7832 g) and HBTU 
(3.1435 g) in dry DMF (100 mL) were deoxygenated with nitrogen. Triethylamine (2.4 mL) was 
added and the reaction mixture was stirred at room temperature for 12 hours. The reaction 
mixture was filtered and CH2Cl2 (100 mL) was added to the yellow filtrate which was extracted 
with 0.1 M HCl (100 mL, 2 x), 1 M HCl (100 mL), saturated aqueous NaHCO3 (100 mL), and 
saturated aqueous KCl (100 mL). The organic fraction was collected and concentrated with 
nitrogen. The fraction was reprecipitated in hexanes, and the solid was collected by vacuum 
filtration and dried (yield = 57%). 1H NMR (CD3Cl) δ 0.81 ppm (3H, d), 0.85 (3H, d), 1.46 (1H, 
m), 1.54 (2H, m), 3.95 (2H, d), 4.17 (1H, m), 4.98 (2H, q), 5.45 (1H, d), 7.22 (5H, m), 7.34 (1H, 
m). 
 
Synthesis of [Ru(tpy)(bpy)(Cbz-Leu-NHCH2CN)](PF6)2 
[Ru(tpy)(bpy)Cl](PF6) (30 mg, 0.0447 mmol), Cbz-Leu-NHCH2CN (40.6 mg, 0.134 mmol), and 
AgBF4 (27.7 mg, 0.142 mmol) in 20 mL EtOH were heated at reflux overnight while shielded 
from light. The reaction mixture was cooled in an ice bath and filtered through celite and rinsed 
with EtOH. The reaction mixture was stirred with NH4PF6 and H2O. Air was blown over the 
reaction mixture to remove EtOH while shielded from light. The solid was collected by vacuum 
filtration, and dissolved in acetone and centrifuged to remove excess ligand. The acetone 
solution was then reprecipitated in diethyl ether and collected by vacuum filtration. 1H NMR 
((CD3)2CO) δ 0.23 ppm (t, 2H), 0.40 (s, 2H), 0.58 (m, 2H), 0.73 (m, 2H), 2.68 (q, 1H), 3.16 (m, 
1H), 3.32 (d, 1H), 3.38 (d, 1H), 4.14 (q, 2H), 5.73 (d, 1H) 6.36 (td, 1H), 6.46 (s, 5H), 6.62 (td, 
3H), 6.76 (dt, 1H), 7.15 (m, 6H), 7.56 (m, 2H), 7.79 (t, 2H), 7.97 (d, 2H), 8.03 (d, 1H), 8.98 (d, 
1H). 
 
Synthesis of [Ru(tpy)(dppn)(Cbz-Leu-NHCH2CN)](PF6)2  
[Ru(tpy)(dppn)Cl](PF6) (30 mg, 0.0354 mmol), Cbz-Leu-NHCH2CN (107 mg, 0.353 mmol) and 
AgBF4 (27.6 mg, 0.142 mmol) in 20 mL EtOH were deoxygenated with nitrogen and heated at 
reflux for 7 hours while shielded from light. The reaction mixture was cooled to room 
temperature and filtered to remove impurities. The filtrate was a bright orange solution and was 
stirred with NH4PF6 and H2O while nitrogen was blown over the filtrate to remove EtOH. The 
solid was collected by vacuum filtration and was dissolved in acetone. The solution was 
reprecipitated in diethyl ether and the solid was collected by vacuum filtration. 1H NMR 
((CD3)2CO) δ 1.25 ppm (s, 1H), 1.51 (m, 3H), 1.66 (m, 1H), 2.66 (m, 1H), 2.80 (m, 4H), 4.08 (m, 1H), 
4.33 (d, 2H), 5.00 (dd, 2H), 6.62 (d, 1H), 7.30 (s, 5H), 7.40 (t, 2H), 7.68 (m, 3H), 7.97 (t, 1H), 8.01 (t, 
2H), 8.07 (dd, 1H), 8.11 (t, 2H), 8.33 (m, 2H), 8.50 (t, 1H), 8.57 (dd, 1H), 8.72 (d, 2H), 8.88 (d, 2H), 9.04 
(s, 1H), 9.13 (s, 1H), 9.40 (dd, 1H), 9.92 (dd, 1H), 10.28 (dd, 1H). 
 
Instrumentation: 
1H NMR spectra were collected with a Bruker 250 MHz DPX spectrometer for bpy containing 
complexes and a Bruker 400 MHz DPX spectrometer for dppn containing complexes. Steady 
state absorption spectra were recorded on a Hewlett-Packard 8453 diode array spectrometer. 
Emission data for 1O2 production quantum yields and room temperature and 77 K steady-state 
emission experiments were collected on a Horiba Fluoromax-4 spectrometer. Photolysis and 
ligand exchange quantum yield experiments were performed with a 150 W Xe arc lamp 
(USHIO) in a Miliarch lamp housing unit that was powered by an LPS-220 power supply 
equipped with an LPS-221 igniter (all from PTI). Bandpass filters (Thorlabs) and long pass 
filters (CVI Melles Griot) were used to select the appropriate excitation wavelengths. 
 
Methods: 
1H NMR was performed in methanol-d4 for [Ru(tpy)(bpy)Cl](PF6), acetonitrile-d3 for 
[Ru(tpy)(bpy)(CH3CN)](PF6)2, dichloromethane-d2 for [Ru(tpy)(dppn)Cl](PF6), acetone-d6 for 
[Ru(tpy)(dppn)(CH3CN)](PF6)2, [Ru(tpy)(bpy)(CBZ-Leu-NHCH2CN)](PF6)2, and 
[Ru(tpy)(dppn)(CBZ-Leu-NHCH2CN)](PF6)2.  
 
Quantum yield of 1O2 production was measured with [Ru(bpy)3]
2+ as a standard (Φ = 0.81)[25] 
and 1,3-diphenylisobenzofuran (DPBF) as a 1O2 trap. Samples were measured in CH3CN in a 1 × 
1 cm quartz cuvette. The samples were absorption matched at the irradiation wavelength (A = 
0.01 at 460 nm). The samples were irradiated in the presence of 1.0 μM DPBF and the decreased 
emission of DPBF was monitored as a function of time (λexc = 405 nm and λem = 479 nm). A plot 
of the emission intensity vs irradiation time provided a linear trend. The slope for 
[Ru(tpy)(dppn)(CH3CN)]
2+ was compared to that of [Ru(bpy)3]
2+ to afford the quantum yield. 
 
Samples were measured in CH3CN in a 1 x 1 cm quartz cuvette for room temperature 
experiments. Samples at 77 K were placed in an NMR tube in a quartz finger dewar containing 
liquid N2. The dewar was mounted in the sample compartment of a Horiba Fluoromax-4 
spectrometer. For both room temperature and 77 K emission experiments, samples were excited 
with λexc = 450 nm. For the excitation experiments, the emission was monitored at 600 nm at 77 
K and 625 nm at room temperature. The emission and excitation signals were corrected for 
detector response. 
   
The ligand exchange quantum yields were measured with an irradiation wavelength of 450 nm in 
H2O with 10% acetone. Potassium tris(ferrioxalate) was used as the chemical actinometer to 
determine the photon flux of the lamp. [26]  
  
Results and Discussion 
Synthesis 
The reaction scheme for the synthesis of [Ru(tpy)(NN)(NCCH3)](PF6)2 is shown in Scheme 1. 
The first step involves the preparation of Ru(tpy)Cl3 from RuCl3·3H2O. The resulting Ru(tpy)Cl3 
complex was then reacted with the desired bidentate ligand, NN = bpy or dppn, to form the 
corresponding [Ru(tpy)(NN)Cl](PF6) complex. The final step involved the replacement of the 
chloride ligand with acetonitrile. The reaction scheme for the synthesis of [Ru(tpy)(NN)(Cbz-
Leu-NHCH2CN)](PF6)2 (NN = bpy, dppn) is shown in Scheme 1. The synthesis is similar to the 
synthesis for [Ru(tpy)(NN)(NCCH3)](PF6)2, however in the last step the chloride ligand is 
replaced with the drug molecule.  The schematic representation of the molecular structure of the 
complexes is shown in Figure 3. 
 
Scheme 1: Synthesis of [Ru(tpy)(NN)(L)]2+ where NN = bpy or dppn and L = CH3CN or Cbz-Leu-NHCH2CN. 
Structure 
The 1H-NMR spectra for [Ru(tpy)(bpy)(CH3CN)]
2+ in (CD3)CO is shown in Figure 4 and the 
labeling scheme appears in Figure 3. A resonance integrating to 3H was observed at 2.07 ppm 
corresponding to the CH3CN ligand bound to the ruthenium center (labeled c). The farthest 
downfield resonance in the spectrum was observed at 9.56 ppm and integrates to 1H, 
corresponding to the bpy proton pointing towards the acetonitrile ligand (labeled a). The 1H-
NMR spectra for [Ru(tpy)(dppn)(CH3CN)]
2+ in (CD3)CO is shown in Figure 5. A resonance 
integrating to 3H was observed at 2.43 ppm corresponding to the CH3CN ligand bound to the 
ruthenium center (labeled c). The farthest downfield resonance was observed at 10.35 ppm 
which integrates to 1H corresponding to the dppn proton pointing towards the acetonitrile ligand 
(labeled a). Two singlet resonances that both integrate to 1H were observed at 9.15 and 9.25 ppm 
(labeled b). These resonances correspond to the protons on the dppn backbone. 
 
Figure 3: Structure of [Ru(tpy)(NN)CH3CN]2+ where the structure of the bpy ligand is shown in red, and the dppn 
ligand is comprised of both the red and blue structures. Small letters indicate proton assignments for the 1H-NMR 
spectra below. 
 Figure 4: 1H NMR spectra of [Ru(tpy)(bpy)(CH3CN)]2+ 
a 
c 
 Figure 5: 1H NMR spectra of [Ru(tpy)(dppn)(CH3CN)]2+ 
 
The molecular structure of [Ru(tpy)(bpy)(CBZ-Leu-NHCH2CN]
2+ is depicted in Figure 6 (with 
proton labeling scheme) and its 1H NMR spectrum in (CD3)CO is shown in Figure 7. A 
resonance integrating to 5H was observed at 6.46 ppm corresponding to the 5 protons of the 
phenyl ring in the inhibitor (labeled c). The farthest downfield resonance in the spectrum was 
observed at 8.98 ppm which integrates to 1H and corresponds to the bpy proton pointing towards 
the inhibitor (labeled a). This resonance has shifted between the acetonitrile and inhibitor 
complexes as the inhibitor is less electron withdrawing allowing the proton to be more shielded. 
a 
b, b 
c 
The 1H-NMR spectra for [Ru(tpy)(dppn)(CBZ-Leu-NHCH2CN)]
2+ in (CD3)CO is shown in 
Figure 8 and the structure of the molecule in Figure 6. A resonance integrating to 5H was 
observed at 7.30 ppm corresponding to the 5 phenyl protons of the inhibitor (c). The farthest 
downfield resonance was observed at 10.28 ppm integrating to 1H corresponds to the dppn 
proton pointing towards the inhibitor (a). Two singlet resonances that both integrate to 1H were 
observed at 9.04 and 9.13 ppm and corresponding to the dppn backbone protons (b). 
 
Figure 6: Structure of [Ru(tpy)(NN)(Cbz-Leu-NHCH2CN]2 where the structure of the bpy ligand is shown in red, and 
the dppn ligand is comprised of both the red and blue structures. Small letters indicate proton assignments for the 1H-
NMR spectra below. 
 Figure 7: 1H NMR of [Ru(tpy)(bpy)(Cbz-Leu-NHCH2CN)]2+ 
a 
c 
 Figure 8: 1H NMR of [Ru(tpy)(dppn)(Cbz-Leu-NHCH2CN)]2+ 
 
The electronic absorption spectrum of each complex in acetone exhibits a maximum at ~455 nm 
(Table 1), corresponding to the Ru→tpy and Ru→bpy/dppn metal-to-ligand charge transfer 
(1MLCT) transitions. The bpy and dppn containing complexes have similar MLCT energies, 
indicating the proximal orbitals of dppn are not communicating electronically with the distal 
orbitals. In the dppn complexes, there are also maxima at 388 nm and 410 nm known to arise 
from ligand-centered 1ππ* transitions of dppn (Table 1).  
 
 
a 
b, b 
c 
Table 1. Maxima Observed in the Electronic Absorption Spectrum of Each Complex in Water 
with 10% Acetone. 
Complex 1MLCT (λ / nm) 1ππ* (λ / nm) 
[Ru(tpy)(bpy)(CH3CN)]
2+ 454 - 
[Ru(tpy)(bpy)(CBZ-Leu-NHCH2CN)]
2+ 449 - 
[Ru(tpy)(dppn)(CH3CN)]
2+ 452 388, 410  
[Ru(tpy)(dppn)(CBZ-Leu-NHCH2CN)]
2+ 448 389, 410 
 
A solution of each acetonitrile complex in acetonitrile was excited with λex = 450 nm at 77 K. 
Both complexes exhibit emission with a peak near 600 nm (Table 2) consistent with the triplet 
metal-to-ligand charge transfer (3MLCT) transition (Figure 9). There is a shoulder in the 
emission band near 650 nm (Table 2), corresponding to an energy difference between the peak 
and shoulder of 1150 cm-1 (Table 2). This energy difference corresponds to the energy difference 
in the vibrational levels of the ground state of each complex, as emission occurs from the lowest 
vibrational state of the 3MLCT to discrete vibrational levels of the ground state. At low 
temperatures, the difference in energy between these transitions is resolved enough to be visible.  
 
The complexes are very weakly emissive at room temperature (Figure 10), and the emission 
maxima for both complexes is red shifted compared to those at 77 K (Table 2). While emission is 
still occurring from the lowest possible energy vibrational level in the 3MLCT state, relaxation is 
occurring to higher vibrational levels in the ground state, leading to lower energy 
phosphorescence. A clear shoulder in the emission spectrum is no longer visible, as more 
vibrational levels are accessible at higher temperatures, and the emission peak is broadened. The 
excitation spectra of the complexes (Figures 9 and 10, shown in gray) match the absorption 
spectra, indicating the emission is occurring from the complexes and does not originate from an 
emissive impurity. 
 
Table 2: Peaks in emission spectra of acetonitrile complexes in acetonitrile at 77K and room temperature. 
Complex λmax - 77 K λshoulder - 77 K ΔE (max, 
shoulder) 
λmax - RT, under 
N2 
[Ru(tpy)(bpy)(CH3CN)]
2+ 608 nm 653 nm 1133 cm-1 624 nm 
[Ru(tpy)(dppn)(CH3CN)]
2+ 598 nm 643 nm 1170 cm-1 625 nm 
 
 
Figure 9  Absorption (blue, 298 K), excitation (grey, 77 K), and emission (orange, 77 K) spectra of (a) 
[Ru(tpy)(bpy)(CH3CN)]2+ and (b)  [Ru(tpy)(dppn)(CH3CN)]2+ in acetonitrile. 
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Figure 10: Absorbance (blue), excitation (grey), and emission (orange) spectra of [Ru(tpy)(bpy)(CH3CN)]2+ (a) and 
[Ru(tpy)(dppn)(CH3CN)]2+ (b) in acetonitrile at room temperature under nitrogen. 
Irradiation into the 1MLCT band of each complex with λirr ≥ 395 nm results in ligand exchange 
in water (10% acetone). For the bpy containing complexes a decrease in the absorption at 455 
nm was observed and a peak at 475 nm grew in (Figure 11, 13). These changes correspond to the 
release of a nitrile ligand and the coordination of a water molecule to form the photoproduct 
[Ru(tpy)(bpy)(H2O)]
2+. The isosbestic points at 378 nm and 463 nm indicate the formation of a 
single photoproduct. For the dppn containing complexes a decrease in the absorption at 455 nm 
and an increase in absorption at 476 nm was observed, corresponding to the release of the nitrile 
ligand and the coordination of a water molecule to form the photoproduct 
[Ru(tpy)(dppn)(H2O)]
2+ (Figure 12, 14). There was also decreased absorption on the ligand 
centered transition peaks at 388 and 410 nm, which was observed both in air and under nitrogen. 
The isosbestic point at 462 nm indicates the formation of a single photoproduct. 
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Figure 10: Photolysis of [Ru(tpy)(bpy)(CH3CN)]2+ in water. 
 
Figure 11: Photolysis of [Ru(tpy)(dppn)(CH3CN)]2+ in water. 
  
Figure 12: Photolysis of [Ru(tpy)(bpy)(CBZ-Leu-NHCH2CN)]2+ 
 
Figure 134: Photolysis of [Ru(tpy)(dppn)(CBZ-Leu-NHCH2CN)]2+ 
 
The drug containing complexes required longer irradiation times for conversion to the aqua 
complex than the acetonitrile complexes. This can be explained due to the size of the drug 
molecule. Since the drug is much larger than acetonitrile, it will diffuse in solution more slowly, 
allowing the drug to re-coordinate after its initial release, instead of being exchanged with a 
water molecule. The solubility of Cbz-Leu-NHCH2CN in water is also lower than that of 
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CH3CN, which also slows the diffusion of the dissociated ligand away from the metal complex, 
thus lowering the ligand exchange efficiency relative to the CH3CN analogue. 
 
The dppn containing complexes also required longer irradiation times than the bpy containing 
complexes as dppn is capable of generating 1O2 from its long-lived 
3ππ* state. The processes of 
ligand exchange and singlet oxygen production are competitive as they arise from two different 
excited states that may be populated from the 1MLCT excited state, making each process less 
efficient than in a complex where only one process is possible.[27] 
 
[Ru(tpy)(dppn)(CH3CN)]
2+ is capable of photoinduced ligand exchange as well as production of 
1O2 for enhanced cellular toxicity. The decrease in emission from the emissive 
1O2 scavenger, 
DPBF, in solution with [Ru(tpy)(dppn)(CH3CN)]
2+ (orange) and [Ru(bpy)3]
2+ (blue) is shown in 
Figure 15. The quantum yield of 1O2 production (ΦΔ) from the 3ππ* state of 
[Ru(tpy)(dppn)(CH3CN)]
2+ was determined to be 0.62(6). This value is lower than the quantum 
yield of 1O2 production of [Ru(bpy)3]
2+ (ΦΔ = 0.81), which was used as a standard, due to the 
competition between the 3LF responsible for ligand dissociation and 3ππ* states responsible for 
the production of 1O2.  
 
 Figure 14: The emission of DPBF as a function of time while being irradiated in solution with a Ru(II) 1O2 producer.  
[Ru(bpy)3]2+ is shown in blue, [Ru(tpy)(dppn)(CH3CN)]2+ is shown in orange.  
Conclusion 
[Ru(tpy)(bpy)(CH3CN)]
2+ and [Ru(tpy)(dppn)(CH3CN)]
2+ were synthesized as models for the 
potential PDT agents, [Ru(tpy)(bpy)(Cbz-Leu-NHCH2CN)]
2+ and [Ru(tpy)(dppn)(Cbz-Leu-
NHCH2CN)]
2+, which were also synthesized and characterized. All four complexes are shown to 
undergo efficient photoinduced ligand exchange in an aqueous environment, and 
[Ru(tpy)(dppn)(CH3CN)]
2+ was shown to efficiently produce singlet oxygen, enhancing the 
proposed cytotoxicity for [Ru(tpy)(dppn)(Cbz-Leu-NHCH2CN)]
2+. 
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